Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP...
-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 24, 2022 10:45am
$HMTXF common share and warrant elaboration
The recently announced private placement of 15 million units has put the entire OTC in awe, in which each full unit consists of one common share and one purchase warrant, each full warrant entitles
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 24, 2022 10:28am
$HMTXF announced closure of the first tranche of the unit pr
$HMTXF have successfully closed the first tranche of the announced on May 29. 2 022 for gross proceeds of $690,388.80. The Offering contained the issuance of a collective of 2,301,296 Units at a
...more
Discover Options Trading Strategies to Minimize your Tax Burden
posted Dec 01, 2024 9:00am by
Bank of Montreal
-
|
Options trading doesn’t come without tax implications, but there are ways investors can still optimize their after-tax returns with just a little bit of understanding. Approaches for investors to keep in mind are holding periods, wash-sales rule, tax advantaged accounts, and qualified cover calls. BMO’s enhanced InvestorLine platform. Industry-leading tools and capabilities specifically designed to empower options traders. ...read more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 24, 2022 9:45am
$HMTXF get backs all its intellectual property
Hemostemix is now in possession of all of its intellectual property, including all HS 12-01 Phase II clinical trial data, all historical data from Hemostemix Israel, and the randomization tables that
...more
(13)
•••
trade007
X
View Profile
View Bullboard History
Post by
trade007
on Jun 24, 2022 8:37am
CEO Hemostemix highlighted the mounting demand of $HEM.
Thomas Smeenk on the latest update stated “for the stem cell space it is the right time to take a bite of the apple” Thomas later said the management board have invested about $4.5 Million in the
...more
(26)
•••
GustheGreek
X
View Profile
View Bullboard History
Comment by
GustheGreek
on Jun 24, 2022 8:15am
RE:Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) keeping investors o
Note the final sentence, "HEM and HMTXF are surely a commendable investment as the stocks exhibit explosive nature and aggressive bull run is en-route for the stock". Interesting....
(2)
•••
zames007
X
View Profile
View Bullboard History
Post by
zames007
on Jun 23, 2022 3:35pm
CEO Hemostemix highlighted the mounting demand of $HEM.
Thomas Smeenk on the latest update stated “for the stem cell space it is the right time to take a bite of the apple” Thomas later said the management board have invested about $4.5 Million in the
...more
(7)
•••
TRADERCONNECTS
X
View Profile
View Bullboard History
Post by
TRADERCONNECTS
on Jun 23, 2022 3:17pm
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) keeping investors o
https://investorconnect.livejournal.com/394.html
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 23, 2022 3:07pm
Hemostemix Inc. interest payment on convertible debenture
Hemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder
...more
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 23, 2022 2:35pm
Hemostemix Inc. (OTC: HMTXF) (TSXV: HEM) a worth full stock
https://medium.com/@subash.bluedigitalmedia/hemostemix-inc-otc-hmtxf-tsxv-hem-a-worth-full-stock-investment-72b39525ae3b
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 2:28pm
Hemostemix owns over 91 patents
The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell
...more
(6)
•••
Tradeconnects
X
View Profile
View Bullboard History
Post by
Tradeconnects
on Jun 23, 2022 2:21pm
Hemostemix Announces Closing of UNIT Private Placement
https://www.newsfilecorp.com/redirect/gxkwMHKrkx
(7)
•••
TRADERCONNECTS
X
View Profile
View Bullboard History
Post by
TRADERCONNECTS
on Jun 23, 2022 1:49pm
$HEM recoups legal guardianship of its lost intellectual pro
The company has legally retrieved all intellectual data related to stage 2 clinical trial data, along with all previous data from Hemostemix Israel and the randomized table needed to evaluate ACP-01
...more
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 23, 2022 12:41pm
$HEM announcement related to the Stock Options Grant
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 12:06pm
Hemostemix informs regarding non-brokered private placement
Hemostemix Inc. announces a non-brokered private placement of up to 15 Million Units priced in the context of the market.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 11:58am
The approval of offering by TSX-V
The offering is subject to all the necessary regulatory approvals including acceptance from the exchange. All securities issued in connection with the offering will be subject to a four-month hold
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >